Throughout much of North America, the legal cannabis movement has been unstoppable. Last year, Mexico legalized medical marijuana, while Canada is currently in the final stages of becoming the first developed country in the world to legalize adult-use weed. Even the United States has witnessed steady progression, with 29 states (and Washington, D.C.) passing broad-sweeping medical cannabis laws since 1996.
According to cannabis research firm ArcView, the North American legal pot market generated $9.7 billion in sales last year, which was up 33% from the previous year. Of course, a vast majority of aggregate marijuana sales are still conducted on the black market, giving the industry and investors hope that there's still many years of huge growth that lie ahead.
Image source: Getty Images.
Top Medical Stocks To Watch For 2019: Asia Pacific Fund, Inc. (APB)
Advisors' Opinion:- [By Logan Wallace]
Media coverage about Asia Pacific Fund, Inc. (The) common stock (NYSE:APB) has been trending somewhat positive on Sunday, Accern reports. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Asia Pacific Fund, Inc. (The) common stock earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news stories about the investment management company an impact score of 45.8681605197346 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Top Medical Stocks To Watch For 2019: AbbVie Inc.(ABBV)
Advisors' Opinion:- [By Cory Renauer]
Gilead Sciences isn't expecting any top-line revenue growth in 2019 because expiring U.S. patents for Letairis and Ranexa could lead to a loss of around $1.2 billion. The company also expects around $900 million in lost sales because of competition with AbbVie (NYSE:ABBV) for a share of a hepatitis C antiviral (HCV) market that's been steadily shrinking. Total HCV sales plummeted from $9.1 billion in 2017 to just $3.7 billion in 2018, and Gilead's new cellular cancer therapy, Yescarta, is proving more difficult to sell than anticipated.
- [By Ethan Ryder]
Cambridge Investment Research Advisors Inc. grew its holdings in AbbVie Inc. (NYSE:ABBV) by 10.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 202,105 shares of the company’s stock after buying an additional 19,119 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in AbbVie were worth $19,546,000 as of its most recent SEC filing.
- [By Stephan Byrd]
Weatherly Asset Management L. P. lowered its stake in AbbVie Inc (NYSE:ABBV) by 20.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,157 shares of the company’s stock after selling 2,317 shares during the quarter. Weatherly Asset Management L. P.’s holdings in AbbVie were worth $867,000 as of its most recent filing with the Securities and Exchange Commission.
- [By Keith Speights]
Shares of Voyager Therapeutics (NASDAQ:VYGR) were skyrocketing 21.7% higher as of 11:22 a.m. EST on Friday. The small biotech announced a collaboration with AbbVie (NYSE:ABBV) to develop vectorized antibodies to treat Parkinson's disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein.
- [By Todd Campbell]
There are more than 23 million people worldwide with rheumatoid arthritis, and despite current treatments, many patients fail to achieve disease remission or significant reductions in disease activity. The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYSE:ABBV) and Gilead Sciences (NASDAQ:GILD) that work similarly are fast-approaching the Food and Drug Administration's finish line. Are these stocks about to battle for billions of dollars in market share?
Top Medical Stocks To Watch For 2019: Ligand Pharmaceuticals Incorporated(LGND)
Advisors' Opinion:- [By Shane Hupp]
Get a free copy of the Zacks research report on Ligand Pharmaceuticals (LGND)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Jon C. Ogg]
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was maintained as Buy at Argus, but the firm lowered its target to $150 from $200. The independent research firm noted that recent weakness offers a buying opportunity as the company is believed to be on track to post solid earnings growth over the next several years. Ligand closed up 1.5% at $119.76 on Tuesday, in a 52-week range of $98.56 to $278.62.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Ligand Pharmaceuticals (LGND)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Keith Speights, Chuck Saletta, and Brian Feroldi]
That's the question we presented to three Motley Fool contributors. They identified Ligand Pharmaceuticals (NASDAQ:LGND), Portola Pharmaceuticals (NASDAQ:PTLA), and Supernus Pharmaceuticals (NASDAQ:SUPN) as top biotech stocks to buy in September. Here's why these biotechs stood out:
Top Medical Stocks To Watch For 2019: Christopher & Banks Corporation(CBK)
Advisors' Opinion:- [By Stephan Byrd]
Shares of Commerzbank AG (ETR:CBK) have been assigned an average recommendation of “Hold” from the twenty ratings firms that are currently covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is €10.98 ($12.76).
- [By Shane Hupp]
Cfra set a €9.50 ($11.05) price target on Commerzbank (ETR:CBK) in a report released on Wednesday. The firm currently has a neutral rating on the financial services provider’s stock.
- [By Lisa Levin] Companies Reporting Before The Bell Dollar Tree, Inc. (NASDAQ: DLTR) is expected to report quarterly earnings at $1.23 per share on revenue of $5.56 billion. Express, Inc. (NYSE: EXPR) is projected to report quarterly loss at $0.02 per share on revenue of $466.25 million. Dollar General Corporation (NYSE: DG) is estimated to report quarterly earnings at $1.4 per share on revenue of $6.20 billion. Tech Data Corporation (NASDAQ: TECD) is expected to report quarterly earnings at $1.46 per share on revenue of $8.13 billion. Burlington Stores, Inc. (NYSE: BURL) is estimated to report quarterly earnings at $1.09 per share on revenue of $1.49 billion. Ciena Corporation (NYSE: CIEN) is projected to report quarterly earnings at $0.3 per share on revenue of $726.56 million. American Eagle Outfitters, Inc. (NYSE: AEO) is expected to report quarterly earnings at $0.22 per share on revenue of $806.17 million. Titan Machinery Inc. (NASDAQ: TITN) is estimated to report quarterly loss at $0.08 per share on revenue of $276.27 bmillion. Donaldson Company, Inc. (NYSE: DCI) is projected to post quarterly earnings at $0.52 per share on revenue of $682.68 million. Ship Finance International Limited (NYSE: SFL) is expected to report quarterly earnings at $0.21 per share on revenue of $92.08 million. Perry Ellis International, Inc. (NASDAQ: PERY) is projected to report quarterly earnings at $0.67 per share on revenue of $232.30 million. Kirkland's, Inc. (NASDAQ: KIRK) is estimated to report quarterly loss at $0.09 per share on revenue of $140.83 million. Build-A-Bear Workshop, Inc. (NYSE: BBW) is expected to report quarterly earnings at $0.18 per share on revenue of $90.20 million. J.Jill, Inc. (NYSE: JILL) is projected to report quarterly earnings at $0.19 per share on revenue of $160.50 million. Christopher & Banks Corporation (NYSE: CBK) is expected to report quarterly loss at $0.08 per share on revenue of $89.35 million.
- [By Logan Wallace]
Commerzbank (ETR:CBK) received a €10.00 ($11.63) target price from equities researchers at Morgan Stanley in a report released on Wednesday. The firm presently has a “neutral” rating on the financial services provider’s stock. Morgan Stanley’s target price would indicate a potential upside of 14.60% from the stock’s current price.
- [By Joseph Griffin]
Christopher & Banks Co. (NYSE:CBK) reached a new 52-week high and low during mid-day trading on Thursday . The stock traded as low as $0.75 and last traded at $0.81, with a volume of 12488 shares changing hands. The stock had previously closed at $0.89.
- [By Logan Wallace]
Independent Research set a €9.50 ($11.05) target price on Commerzbank (ETR:CBK) in a report published on Thursday morning. The brokerage currently has a neutral rating on the financial services provider’s stock.
Top Medical Stocks To Watch For 2019: Globus Maritime Limited(GLBS)
Advisors' Opinion:- [By Joseph Griffin]
Media coverage about Globus Maritime (NASDAQ:GLBS) has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Globus Maritime earned a news impact score of 0.09 on Accern’s scale. Accern also assigned news articles about the shipping company an impact score of 45.6853785900783 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
- [By Money Morning Staff Reports]
After looking at last week's top performing penny stocks, we'll show you a penny stock that's on the verge of crushing Cherokee's returns…
Penny Stock Current Share Price Last Week's Gain Cherokee Inc. (Nasdaq: CHKE) $0.82 91.11 % Checkpoint Therapeutics Inc. (Nasdaq: CKPT) $3.54 51.62% TMRS Holding Co. Ltd. (Nasdaq: TMSR) $4.43 50.00% EKSO Bionics Holdings Inc. (Nasdaq: EKSO) $2.58 46.93% Jones Energy Inc. (NYSE: JONE) $0.47 46.76% TransAtlantic Petroleum Corp. (NYSE: TAT) $1.39 44.29% Inseego Corp. (Nasdaq: INSG) $2.70 42.27% Globus Maritime Ltd. (Nasdaq: GLBS) $0.44 37.85% iFresh Inc. (Nasdaq: IFMK) $2.81 33.64% Technical Communications Corp. (Nasdaq: TCCO) $4.88 29.87%While all of last week's 10 top penny stocks generated great returns, it's unlikely that they will be able to deliver these kinds of profits again anytime soon.
No comments:
Post a Comment